John Libbey Eurotext

European Journal of Dermatology


Infliximab in recalcitrant generalized pustular arthropatic psoriasis Volume 18, issue 1, January-February 2008


See all figures

Dermatology Department, Hospital dos Capuchos, Alameda Santo António dos Capuchos, 1150 – 314 Lisboa, Portugal
  • Key words: anti-TNF-alpha, arthropatic, biologics, infliximab, pustular psoriasis
  • DOI : 10.1684/ejd.2008.0314
  • Page(s) : 71-3
  • Published in: 2008

Generalized pustular psoriasis is an unstable inflammatory type of psoriasis, with widespread areas of erythema and sterile pustules, associated with fever and systemic symptoms. Infliximab is a monoclonal antibody with anti-TNFα activity, approved for use in psoriasis. We describe a male patient with a long history of stable arthropathic psoriasis, hospitalized with a generalized pustular psoriasis and acute exacerbation of articular complaints. The disease was resistant to multiple therapies (acitretin, methotrexate and corticosteroids), so the patient was started on infliximab, with a very rapid response of both cutaneous and articular symptoms. He had complete clearing of lesions at week 12, and marked improvement of the articular symptoms. No recurrence occurred at 8 months of follow-up with infliximab every 8 weeks. Infliximab had an extremely rapid therapeutic action response on a recalcitrant generalized pustular psoriasis. The articular response was also excellent, with significant improvement of quality of life.